During the last session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares were 4.31 million, with the beta value of the company hitting 0.83. At the end of the trading day, the stock’s price was $7.84, reflecting an intraday loss of -1.26% or -$0.1. The 52-week high for the RXRX share is $16.75, that puts it down -113.65 from that peak though still a striking 42.09% gain since the share price plummeted to a 52-week low of $4.54. The company’s market capitalization is $1.69B, and the average trade volume was 6.34 million shares over the past three months.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Recursion Pharmaceuticals Inc (RXRX) registered a -1.26% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.26% in intraday trading to $7.84, hitting a weekly high. The stock’s 5-day price performance is 5.95%, and it has moved by -24.03% in 30 days. Based on these gigs, the overall price performance for the year is 51.64%.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Statistics show that Recursion Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Recursion Pharmaceuticals Inc (RXRX) shares have gone up 29.37% during the last six months, with a year-to-date growth rate less than the industry average at -3.16% against 10.20. In the rating firms’ projections, revenue will increase 26.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 12.65M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 13.17M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 12.13M and 11.02M respectively. In this case, analysts expect current quarter sales to grow by 4.30% and then jump by 19.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.41%. While earnings are projected to return -9.14% in 2024, the next five years will return 12.00% per annum.
RXRX Dividends
Recursion Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
